NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Optipranolol (metipranolol hydrochloride) is a non-selective beta-adrenergic antagonist ophthalmic solution approved for treating elevated intraocular pressure in glaucoma and ocular hypertension. It reduces aqueous humor production and increases uveoscleral outflow, lowering intraocular pressure through beta-blockade in the eye.
LOE Approaching
As LOE approaches, expect team contraction and focus on lifecycle extension or market transition strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, declining lifecycle stage; roles available are typically maintenance-focused rather than growth or innovation-driven. Career mobility on Optipranolol is limited; professionals should view assignment as stable but offer limited advancement opportunity compared to growth-stage portfolios.
Brand ManagerField Sales Representative
Worked on OPTIPRANOLOL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.